Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled | Starlite/ChEMBL | References |
Homo sapiens | 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled | Starlite/ChEMBL | References |
Homo sapiens | 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | AT19640p | 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled | 390 aa | 335 aa | 21.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0159 | 0.01 | 0.5 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0159 | 0.01 | 0.5 |
Plasmodium falciparum | thioredoxin reductase | 0.0458 | 1 | 1 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0159 | 0.01 | 0.5 |
Echinococcus multilocularis | dihydrolipoamide dehydrogenase | 0.0159 | 0.01 | 0.01 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0159 | 0.01 | 0.5 |
Brugia malayi | Serotonin/octopamine receptor family protein 7 | 0.0366 | 0.695 | 0.692 |
Treponema pallidum | NADH oxidase | 0.0159 | 0.01 | 0.5 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0159 | 0.01 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0321 | 0.5473 | 0.5473 |
Schistosoma mansoni | biogenic amine (octopamine/dopamine) receptor | 0.0366 | 0.695 | 0.695 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0159 | 0.01 | 0.5 |
Schistosoma mansoni | dihydrolipoamide dehydrogenase | 0.0159 | 0.01 | 0.01 |
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.695 | 0.695 |
Plasmodium falciparum | glutathione reductase | 0.0458 | 1 | 1 |
Leishmania major | trypanothione reductase | 0.0458 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0159 | 0.01 | 0.5 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0458 | 1 | 1 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0159 | 0.01 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0366 | 0.695 | 0.695 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0458 | 1 | 1 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0159 | 0.01 | 0.5 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0458 | 1 | 1 |
Echinococcus granulosus | dihydrolipoamide dehydrogenase | 0.0159 | 0.01 | 0.01 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0458 | 1 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0159 | 0.01 | 0.5 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0458 | 1 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0458 | 1 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0458 | 1 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0458 | 1 | 1 |
Plasmodium vivax | glutathione reductase, putative | 0.0458 | 1 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0458 | 1 | 1 |
Trypanosoma brucei | trypanothione reductase | 0.0458 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Antagonism (functional) | = 47 % | Antagonism of the compound tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT) | ChEMBL. | 9397179 |
Antagonism (functional) | = 47 % | Antagonism of the compound tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT) | ChEMBL. | 9397179 |
EC50 (functional) | = 30 nM | Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation | ChEMBL. | 9397179 |
EC50 (functional) | = 30 nM | Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation | ChEMBL. | 9397179 |
Emax (binding) | = 69 % | Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor | ChEMBL. | 9397179 |
Emax (binding) | = 69 % | Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor | ChEMBL. | 9397179 |
Ki (binding) | = 0.44 nM | Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells | ChEMBL. | 9397179 |
Ki (binding) | = 0.44 nM | Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells | ChEMBL. | 9397179 |
Ki (binding) | = 0.62 nM | Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells | ChEMBL. | 9397179 |
Ki (binding) | = 0.62 nM | Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells | ChEMBL. | 9397179 |
Ki (binding) | = 13.4 nM | Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells | ChEMBL. | 9397179 |
Ki (binding) | = 13.4 nM | Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells | ChEMBL. | 9397179 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.